about
Amyloid-β and Astrocytes Interplay in Amyloid-β Related DisordersDiagnosis and management of behavioral variant frontotemporal dementiaThe advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)Magnetic resonance spectroscopy in the diagnosis of dementia with Lewy bodies.Use of antidementia drugs in frontotemporal lobar degeneration.Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.Late-onset cinephilia and compulsive behaviors: harbingers of frontotemporal dementiaMedical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategiesDiagnosis and management of behavioral issues in frontotemporal dementiaMemantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial.FTD and ALS: a tale of two diseasesPractical utility of amyloid and FDG-PET in an academic dementia center.Frontotemporal lobar degeneration: current perspectives.Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease.Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.Progress in frontotemporal dementia research.Clinical Subtypes of Frontotemporal Dementia.Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials.Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective.Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review.Dementia: A complex disease with multiple etiologies and multiple treatments.Frontotemporal dementia and psychiatry.EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia.
P2860
Q26766934-06E9115A-AC0D-4701-B308-6CAD29954CABQ27006258-F33FCD8A-AE63-433C-B828-806FF025A821Q28485924-6F8AB584-9023-43C1-9CF7-05E455F2DD5FQ30841801-68090E48-392E-4961-98AD-866321858B4BQ34273321-C137203B-5D50-4064-AAEE-383704CFF5B1Q35107027-8722AB54-6E90-4010-92B2-CAFFC490DB0FQ35251909-6633E9D7-4739-49F9-8482-5AA96E73E334Q35523924-6E40780F-8DF5-48C9-927F-943652C6E5DFQ36238717-93B3C7D2-F758-4119-8FFA-A6CD5972A292Q37131376-82C21C2F-F46E-4ED7-B99D-B614C9CC6432Q37241079-FE55B7F2-892B-49A4-9EBB-C68FB5A86DFEQ37518041-477E2111-331E-4170-BFFA-FEF0F14E2514Q37591327-6C9E0315-7841-4970-97CB-FDE5585236E4Q37610784-54133390-9C72-483C-A721-5B1557076C2CQ38040822-905A8A8A-1A2C-4E39-BDE0-E1E689B82700Q38065721-3B9D6D5E-6627-4AEE-A506-549C3115593CQ38118236-144989ED-3435-4AF9-A662-0ACE438AD9C8Q38155959-260805E1-B44E-487A-89ED-2BCC5BBBBA0AQ38172172-89EC217D-4C83-4B2B-B884-81C01F87C546Q38391397-ABDC0D9A-8606-41A4-AF4E-13D0525A4CFBQ38738414-8B394A34-0F3E-42E9-B664-9C81B3AC203EQ38760122-F04185DD-4857-4D9C-8979-09E10CF1D5D7Q42416391-E3830A94-2404-462D-AD47-712B9B6CEDE6Q45289583-E691A838-72DA-4715-928C-1396BB20012F
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Off-label medication use in frontotemporal dementia.
@ast
Off-label medication use in frontotemporal dementia.
@en
type
label
Off-label medication use in frontotemporal dementia.
@ast
Off-label medication use in frontotemporal dementia.
@en
prefLabel
Off-label medication use in frontotemporal dementia.
@ast
Off-label medication use in frontotemporal dementia.
@en
P2093
P2860
P50
P356
P1476
Off-label medication use in frontotemporal dementia.
@en
P2093
Bradley Boeve
Joel Kramer
John Neuhaus
Leslie Ross
Mario F Mendez
Neill Graff-Radford
Richard J Caselli
P2860
P304
P356
10.1177/1533317509356692
P407
P577
2010-02-01T00:00:00Z